Recent Leukemia News

Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation

(November 29, 2018)

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata... Continue Reading


FDA Approves Venclexta Combination for AML in Adults

(November 26, 2018)

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid... Continue Reading


duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

(September 25, 2018)

The Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic... Continue Reading


Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation

(July 23, 2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a... Continue Reading


FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion,

(June 25, 2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion,... Continue Reading


Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia

(March 22, 2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the... Continue Reading


CRISPR Enhances Cancer Immunotherapy

(March 14, 2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve... Continue Reading


U.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute Promyelocytic Leukemia

(January 31, 2018)

CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed... Continue Reading


FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia

(January 14, 2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP)... Continue Reading


Pass it On: It’s Leukemia National Awareness Month

(September 19, 2017)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia... Continue Reading


Next Page »